Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

http://www.bio-itworldexpo.com/Bio-It_Expo_Content.aspx?id=140955

  #BioIT17

TUESDAY, MAY 23

7:00 am Workshop Registration and Morning Coffee

8:00 – 11:30 Recommended Morning Pre-Conference Workshops*

(W4) Data Visualization to Accelerate Biological Discovery

12:30 – 4:00 pm Recommended Afternoon Pre-Conference Workshops*

(W13) Proteogenomics: Integration of Genomics and Proteomics Data

* Separate registration required.

2:00 – 6:00 Main Conference Registration Open

4:00 PLENARY KEYNOTE SESSION

Click here for detailed information

5:00 – 7:00 Welcome Reception in the Exhibit Hall with Poster Viewing

WEDNESDAY, MAY 24

7:00 am Registration Open and Morning Coffee

8:00 PLENARY KEYNOTE SESSION

Click here for detailed information

9:50 Coffee Break in the Exhibit Hall with Poster Viewing

APPLICATIONS & SOLUTIONS FOR DATA SHARING AND DECISION MAKING

10:50 Chairperson’s Remarks

Kevin Merlo, BioSafety Development Engineer, Dassault Systemes

11:00 Innovative Data Integration Applicable for Therapeutic Protein Development 2.0

Wolfgang Paul, Group Leader and Senior Scientist, Large Molecule Research, Roche

Therapeutic proteins are registered including sequence, structural and functional data and information. Millions of data points are captured during the development of Roche’s innovative therapeutic proteins in data warehouse used by DAMAS (data acquisition, management and analyses system). Fast access and visualization of relevant process and analytical data drive scientific discussion and decision making. Analyzing the stored big data is key towards process development of therapeutic proteins 2.0.

11:30 Informatics – A Silver Bullet for Pharmaceutical Sciences?

William Loging, Ph.D., Associate Professor of Genomics & Head, Production Bioinformatics, Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai

The Pharmaceutical Sciences field is in constant search for the next big innovative push that will increase the success rate of drug programs. The fields of computational chemistry, structural bioinformatics – just to name a few – have changed the way drug researchers look for and identify novel drug candidates. Utilizing more than 15 years of Pharmaceutical experience, and using real world examples of high provide drug projects, this talk will provide practical steps for the merger of informatics and the strategic approaches needed for drug discovery success.

12:00 pm Big Data-Driven Bioinformatics

Frank Lee, Ph.D., Healthcare Life Sciences Industry Leader, Software Defined Infrastructure, IBM Systems, IBM

IBM will discuss the IBM Reference Architecture for Genomics, its new features, and case studies: hybrid cloud with integrated workload and data management for high performance genomics analytics; container technologies for migrating and sharing application and data; and application portal and metadata engine for global access to and searching of distributed resources. A demo of a hybrid cloud-based bioinformatics solution will follow.

12:30 Session Break

12:40 Luncheon Presentation I to be Announced

1:10 Luncheon Presentation II to be Announced

1:40 Session Break

STANDARDS FOR CHEMICAL STRUCTURES

1:50 Chairperson’s Remarks

1:55 PANEL DISCUSSION: Linking and Finding Information Using the IUPAC InChI Standard for Chemical Structures

Steve Heller, Ph.D., Project Director, InChI Trust; Scientific Information Consultant (Moderator)

Evan Bolton, Ph.D., Lead Scientist, National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), and National Institutes of Health (NIH)

Keith T. Taylor, BSc, Ph.D., MRSC, Principal, Ladera Consultancy

Tyler Peryea, Informatics Scientist, National Center for Advancing Translational Sciences (NCATS)

Lawrence Callahan, Ph.D., Chemist, Substance Registration System, Office of Critical Path Programs, Food and Drug Administration (FDA)

This session will highlight on-going efforts to strengthen and expand the non-proprietary IUPAC International Chemical Identifier (InChI) standard for chemical structures and its hashed-form, the InChIKey. Information standards are critical to enable effective communication of scientific content. Funding to maintain InChI comes from most major publishers and database providers as well as governmental agencies (NIH, FDA and NIST). The InChI is an open-source, widely adopted standard found in most chemical information containing databases, including those from Chemical Abstracts, Reaxys, ChEMBL, OpenPHACTS, PubChem, DrugBank, PDB, Sigma-Aldrich, and many others, such as internal Pharma corporate databases. InChI is an addition to a database, not a replacement. With the implementation of the ISO identification of medicinal products (IDMP) and the related ISO 11238 standards, adding and having an InChI will allow for an easier, effective, and more complete search for information on a particular drug.

2:55 Sponsored Presentation (Opportunity Available)

3:10 Integrated Informatics for Biologics Discovery

Robert Brown, Ph.D., Vice President, Product Marketing, Dotmatics

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing

MACHINE LEARNING TECHNIQUES AND APPLICATIONS TO PERFORM BIG DATA ANALYTICS ON –OMICS DATA

4:00 Building Disease Networks Using Text Mining and Machine Learning Techniques

Kamal Rawal, Ph.D., Assistant Professor, Biotech and Bioinformatics, Jaypee Institute of Information Technology

Obesity is a global epidemic affecting over 1.5 billion people and is one of the risk factors for several diseases such as type 2 diabetes mellitus and hypertension. We have constructed a comprehensive map of the molecules reported to be implicated in obesity. Using text mining & deep curation strategies combined with omics data, we have explained the therapeutics and side effects of several drugs (i.e., orlistat) at network level.

4:20 Big Data and Systems Biology: From Genome to Phenome (and Everything in Between)

Dan Jacobson, Ph.D., Computational Biologist, Oak Ridge National Laboratory

4:40 Novel Feature Selection Strategies for Enhanced Predictive Modeling and Deep Learning in the Biosciences

Tom Chittenden, Ph.D., D.Phil., Lecturer and Senior Biostatistics and Mathematical Biology Consultant, Harvard Medical School

We have built a robust AI approach that precisely assesses pathogenicity for all genomic missense variants. Coupled with our advanced deepCODE mathematical statistics feature selection strategy for constructing deep learning models, we are able to quantitatively integrate a priori pathway-based biological knowledge with multiple types of high-throughput omics data.

5:00 Network Analysis for Drug Discovery: Benchmarking Results and Best Practices Reported by CBDD Consortium

Marina Bessarabova, Ph.D., Senior Director, Discovery and Translational Science, Life Sciences Professional Services, Clarivate Analytics (Formerly the IP & Science Business of Thomson Reuters)

A large number of advanced approaches to network analysis of -omics data were developed by academia groups in the past 15 years. Adoption of these approaches in drug development requires thorough review of the published approaches, implementation of methods identified as potentially applicable to drug development and benchmarking of the methods with an aim to establish best practices for application of the methods to diseases and mechanism of action understanding, target identification, drug repositioning, patient stratification, biomarker discovery, and drug combination effect prediction. CBDD (Computational Biology Methods for Drug Discovery) is a precompetitive consortium between Novartis, Pfizer, Sanofi, Janssen, Regeneron, UCB, Roche, Takeda, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Merck and Clarivate Analytics (formally Thomson Reuters) focused on adoption of network analysis approaches in drug development: literature review, method implementation and benchmarking. Benchmarking results and best practices for application of network analysis in drug development established by members of the program will be shared during the presentation.

5:30 15th Anniversary Celebration in the Exhibit Hall with Poster Viewing and Best of Show Awards

THURSDAY, MAY 25

7:00 am Registration Open and Morning Coffee

8:00 PLENARY KEYNOTE SESSION & AWARDS PROGRAM

8:05 Benjamin Franklin Awards and Laureate Presentation

8:35 Best Practices Awards Program

8:50 Plenary Keynote

Click here for detailed information

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced

DATA COMPUTING AND BIOINFORMATICS IN AGRO CHEMICALS AND BIOTECHNOLOGY: CHALLENGES AND OPPORTUNITIES

10:30 Chairperson’s Remarks

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

10:40 How Biotech and Big Data Are Changing Agro Industry

Bino John, Ph.D., Computational Biology Group Leader, Dow AgroSciences LLC

More than 70% of the increase in food production in the next 50 years is expected to come from technological advances. Indeed, recent advances in genomics and phenomics are beginning to transform the Agro-industry, whereby creating new opportunities for informatics disciplines. While informatics needs in managing, analyzing, and visualizing big data share commonalties between Agro and the biomedical communities, Agro companies face unprecedented challenges in big biological data, generally larger than their peers in the biomedical community.

11:00 Offering Outcomes: How Digital Farming Data Is Enabling New Business Models

Tobias Menne, Global Head of Digital Farming, Bayer

11:20 Building the Next-Generation R&D IT Infrastructure for Small Molecule Discovery

Paimun Amini, Chemistry IT Lead, R&D IT, Monsanto Company

Barrett Foat, Ph.D., Data Science Team Lead, Agricultural Productivity Innovations, Monsanto

The Pharma boom in the 90s & 2000s led to the emergence of a rich ecosystem of software companies focused on delivering the IT needs for small molecule discovery. Today, cloud data storage, IoT, and the growth of predictive analytics present new opportunities for the evolution of the R&D pipeline. New technologies allow for integrated software and hardware solutions that optimize productivity while removing the risk of technical debt.

11:40 Sponsored Presentation (Opportunity Available)

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing

LOOKING BEYOND THE GENOME OF THE PATIENT: DATA, ANALYSIS AND TOOLS TO IMPROVE BETTER DISEASE UNDERSTANDING FOR CURRENT TREATMENTS AND DRUG DEVELOPMENT

1:55 Chairperson’s Remarks

Michael N. Liebman, Ph.D., Managing Director, IPQ Analytics, LLC and Strategic Medicine, Inc.

2:00 Distinguishing between Precision Medicine and Accurate Medicine: Application to Heart Failure Patients and Clinical Practice

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc.

Increasingly, patient stratification based on genomic analysis is being considered in disease management. Critically, the need to understand real world medical practice and real world patient complexities extends far beyond the genome of the patient. We have shown examples of this complexity in heart disease and how this impacts development of clinical guidelines, trial design, and development of new patient management approaches.

2:30 CARPEDIEM – Comorbidity and Risk Profiles Evaluation in Diabetes and Heart Morbidities

Sabrina Molinaro, Psy.D., Ph.D., Head, Department of Epidemiology and Health Services, Institute of Clinical Physiology, National Research Council of Italy

Our project uniquely develops a patient record that includes clinical and individual factors (EHR-driven phenotyping) that will be validated through the comparison of existing standards for building new risk algorithms. An understanding of the current limitations and biases of risk profiling in heart disease and diabetes and how an extended, integrated database and automatic rule-based classification system can be used to improve patient management.

3:00 PANEL DISCUSSION: Precision Medicine vs. Accurate Medicine: The Need to Understand Real World Medicine and Real World Patients

Michael N. Liebman, Ph.D., IPQ Analytics, LLC and Strategic Medicine, Inc. (Moderator)

Charles Barr, M.D., MPH, Group Medical Director and Head, Evidence Science and Innovation, Genentech

Hal Wolf, Director, National Leader of Information and Digital Health Strategy, The Chartis Group

4:00 Conference Adjourns

SOURCE

http://www.bio-itworldexpo.com/bioinformatics/